Opus Genetics, Inc.

Healthcare · Biotechnology · United States

Last price 3.67 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 305.33M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The company also develops various pre-clinical IRD programs, including OPGx-RHO, a gene therapy that targets ...